Capsugel Completes Acquisitions of Xcelience and Powdersize
News Jan 07, 2016
Capsugel has announced that it has completed its acquisitions of Xcelience and Powdersize. Xcelience and Powdersize are now part of Capsugel's Dosage Form Solutions business unit, which partners with pharmaceutical and health and nutrition customers around the world to advance products through an integrated approach to the design, development and manufacture of high-quality, innovative dosage forms.
The acquisitions, announced on December 14, 2015, provide Capsugel with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms; development and manufacturing for specialized products such as highly potent and controlled substance compounds; and micronization capabilities that augment the company's existing formulation design services and premier bioavailability enhancement technology platform.
When combined with Capsugel’s wide array of industry-leading hard capsule technologies, the expanded capabilities of Capsugel Dosage Form Solutions make the company better positioned than ever to partner with customers to deliver innovative, patient-centric dosage forms and solutions.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019